TNI BioTech, Inc. Granted Additional Patent for Methods for Inducing Sustained Immune Response of T-Cells
ORLANDO, Fla., March 12, 2014 /PRNewswire/ — TNI BioTech, Inc. (OTC: TNIB), a biotech company working to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system using our patented immunotherapy through the acquisition and licensing of late development stage compounds, today announced the U.S. Patent and Trademark Office (USPTO) has granted a key patent for IRT-101 (MENK) for inducing sustained immune response of T-Cells.
The present invention relates to methods of stimulating and promoting a sustained natural immune system response, resulting in increased resistance and inhibition of infectious agents, including viruses, bacteria, fungi and parasites, and other immunodeficiency-related ailments. More specifically, the invention relates to an intermittent dose schedule for promoting a sustained increased level of T-cell production (cytotoxic T-cells) including CD3, CD4, CD8, natural killer (NK) cells, CD38 cells, and interleukin II receptor. Pursuant to the patent, these therapies can be used on immunocompromised individuals including patients with cancer, or undergoing x-ray, surgery, or chemotherapy treatments.
The patent assigned to TNI BioTech from Nicholas Plotnikoff, which is already the subject of a previously granted U.S. patent, protects the activated NK cells. Similar patent protection has been obtained in India, Russia and the United Kingdom.
IRT-101 (MENK) is an active immunotherapy with MENK for patients with deficient functioning of the immune system. It works by restoring the patient’s immune functions and by activating the lymphocytes to attack cancer cells and infectious diseases, such as HIV/AIDS. This is accomplished because MENK binds to opioid receptors on both immune cells and on cancer cells, which directly inhibits the growth of cancer cells and increases the number and functions of T-cells, NK cells, NK-T cells, and gamma/delta T-cells. These cells then destroy infective organisms and tumor cells while simultaneously inhibiting the ability of T regulatory (Treg) cells to block the functions of anti-cancer or anti-infectious disease lymphocytes.
Noreen Griffin, CEO of TNI BioTech said, “We are pleased to be able to expand our patent portfolio and believe this patent plus the many other patents surrounding MENK provide us with broad composition-of-matter protection for our suite of immunotherapy treatments.”
About TNI BioTech, Inc.
TNI BioTech, Inc. is a biotech company working to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system using our patented immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.
Our proprietary technology, therapies and patents include the treatment of a wide range of cancers. Our most advanced clinical programs involve immunotherapy with met-enkephalin (“MENK”) (sometimes referred to as opioid growth factor (“OGF”)) and our Low Dose Naltrexone product (“LDN”), which have been shown to stimulate the immune system even in patients with advanced cancer. Even though management considers any condition that results in altered-immune response a target for investigation, the Company will most likely pursue additional investigations for MENK and LDN as valuable candidates in the treatment of the following: autoimmune states such as rheumatoid arthritis and multiple sclerosis; as an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery; and as an adjunct to antibiotics in the treatment of a variety of infectious diseases, including patients with AIDS, in combination with retroviral drug therapy.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS?
This press release and the statements of representatives and partners of TNI Biotech, Inc. and its subsidiaries (the “Company”) related thereto include various “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the Company’s expectations or beliefs concerning future events. Statements containing expressions such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” used in the Company’s press releases and in the Company’s filings with the Securities and Exchange Commission as well as Disclosure Statements and Reports filed with the Over The Counter Markets through the OTC Disclosure and News Service are intended to identify forward-looking statements. All forward-looking statements involve assumptions and significant risks and uncertainties. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release, and thus readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date thereof. Actual results may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly release any revisions to such forward-looking statements to reflect events or circumstances after the date hereof.
For further information, please see:
Dennis S. Dobson
SOURCE TNI BioTech, Inc.